<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949087</url>
  </required_header>
  <id_info>
    <org_study_id>ORA 18060603</org_study_id>
    <nct_id>NCT04949087</nct_id>
  </id_info>
  <brief_title>Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)</brief_title>
  <acronym>GHOA</acronym>
  <official_title>Prospective, Double Blind, Randomized Control Trial Comparing the Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of intra-articular corticosteroid&#xD;
      injections versus platelet-rich plasma injections for non-operative treatment of primary&#xD;
      glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of&#xD;
      hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are&#xD;
      commonly used with hopes of providing patients with symptomatic relief that can hopefully&#xD;
      delay or prevent the need for shoulder arthroplasty. This study will help elucidate the&#xD;
      therapeutic benefit of corticosteroid and Platelet Rich Plasma (PRP) injections in this&#xD;
      patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blinded, randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale-Pain (VAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Validated patient-reported metric scale of pain: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arthritis Shoulder</condition>
  <arm_group>
    <arm_group_label>Corticosteroid Injection Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg Depo-Medrol and 8cc Lidocaine ultrasound-guided intra-articular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet-Rich Plasma Injection Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15cc blood draw in Arthrex Autologous Conditioned Plasma (ACP) kit and processed per manufacturer instructions Ultrasound-guided intra-articular injection of isolated PRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glenohumeral Injection</intervention_name>
    <description>Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.</description>
    <arm_group_label>Corticosteroid Injection Group</arm_group_label>
    <arm_group_label>Platelet-Rich Plasma Injection Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient â‰¥18y.o. of age&#xD;
&#xD;
          -  Primary glenohumeral arthritis (bone on bone or near bone on bone) that has been&#xD;
             previously diagnosed on radiographs and clinical evaluation.&#xD;
&#xD;
          -  Baseline pain level of VAS &gt;4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary causes of arthritis (i.e. septic arthritis, rheumatoid arthritis, rotator&#xD;
             cuff arthropathy, post-traumatic arthritis)&#xD;
&#xD;
          -  Ipsilateral shoulder surgery within 1 year&#xD;
&#xD;
          -  Any glenohumeral joint injection within 3 months&#xD;
&#xD;
          -  Allergy to lidocaine&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Workers compensation case regarding shoulder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04949087/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

